[Cardiovascular complications of interferon]

Area of Science:

• Cardiology
• Oncology
• Pharmacology

Background:

• Interferon (IFN) is a therapeutic agent used for various cancers and diseases.
• Cardiotoxicity is a known adverse effect of IFN therapy, identified early in clinical trials.

Observation:

• Common, non-serious adverse effects include transient hypotension and atrial extrasystole.
• Less common effects include mild conduction impairment and reversible hypertension.
• Serious toxicities include dose-dependent cardiomyopathy and potentially fatal acute coronary artery failure or ventricular arrhythmias, especially in high-risk patients.

Findings:

• IFN-induced cardiotoxicity presents with a spectrum of severity.
• Life-threatening events like sudden cardiac death can occur, particularly in vulnerable individuals.
• The precise physiopathology of IFN cardiotoxicity remains undetermined.

Implications:

• Rigorous cardiological monitoring is imperative for all patients undergoing IFN treatment.
• Early detection and management of cardiac adverse events are crucial for patient safety.
• Further research into the mechanisms of IFN cardiotoxicity is warranted to improve patient outcomes.